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A B S T R A C T 
_____________________________________________________________________________ 
The acyclic nucleoside phosphonate (ANP2–) 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG) is 
anticancer and antivirally active. The acidity constants of the threefold protonated H3(PMEG)+ 
were determined by potentiometric pH titrations (aq. sol.; 25°C; I = 0.1 M, NaNO3). Under the 
same conditions and by the same method, the stability constants of the binary Cu(H;PMEG)+ and 
Cu(PMEG) complexes as well as those of the ternary ones containing a heteroaromatic N ligand 
(Arm), that is, of Cu(Arm)(H;PMEG)+ and Cu(Arm)(PMEG), where Arm = 2,2'-bipyridine 
(Bpy) or 1,10-phenanthroline (Phen), were measured. The corresponding equilibrium constants, 
taken from our earlier work for the systems with 9-[2-(phosphonomethoxy)ethyl]adenine 
(PMEA) and 9-[2-(phosphonomethoxy)ethyl]-2,6-diamino-purine (PMEDAP) as well as those 
for Cu(PME) and Cu(Arm)(PME), where PME2– = (phosphonomethoxy)ethane = 
(ethoxymethyl)phosphonate, were used for comparisons. These reveal that in the 
monoprotonated ternary Cu(Arm)(H;PE)+ complexes, the proton and Cu(Arm)2+ are at the 
phosphonate group; the ether oxygen of the -CH2-O-CH2-P(O) 2
! (OH) residue also participates to 
some extent in Cu(Arm)2+ coordination. Furthermore, the coordinated Cu(Arm)2+ forms a bridge 
with the purine moiety undergoing π-π stacking which is more pronounced with H·PMEDAP– 
than with H·PMEA–. Most intense is π stack formation (st) with the guanine residue of 
H·PMEG–; here the bridged form Cu(Arm)(H·PMEG) st
+  occurs next to an open (op), unbridged 
(binary) stack, formulated as Cu(Arm)2+/(H·PMEG) op
! . – The unprotonated and neutral ternary 
Cu(Arm)(PE) complexes are considerably more stable than the corresponding Cu(Arm)(R-PO3) 
species, where R-PO 3
2!  represents a phosph(on)ate ligand with a group R that is unable to 
participate in any intramolecular interaction. The observed stability enhancements are mainly 
due to intramolecular stack formation (st) between the aromatic rings of Arm and the purine 
residue in the Cu(Arm)(PE) complexes and also, to a smaller extent, to the formation of five-
membered chelates involving the ether oxygen of the -CH2-O-CH2-PO 3
2!  residue (cl/O) of the 
PE2– species. The quantitative analysis of the intramolecular equilibria reveals three structurally 
different Cu(Arm)(PE) isomers; e.g., of Cu(Phen)(PMEG) ca. 1.1% exist as Cu(Phen)(PMEG)op, 
3.5% as Cu(Phen)(PMEG)cl/O, and 95% as Cu(Phen)(PMEG)st. Comparison of the various 
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formation degrees reveals that within a given Cu(Arm)(PE) series the stacking tendency 
decreases in the order PMEG2– ≥ PMEDAP2– > PMEA2–. Furthermore, stacking is more 
pronounced in the acyclic Cu(Arm)(PE) complexes compared with that in the Cu(Arm)(NMP) 
species, where NMP2– = corresponding parent (2'-deoxy)nucleoside 5'-monophosphate. Here is 
possibly one of the reasons for the biological activity of the ANPs. One is tempted to speculate 
that the pronounced stacking tendency of PMEG2–, together with a different H-bonding pattern, 
leads to enhanced binding in the active site of nucleic acid polymerases, thus being responsible 
for the pronounced anticancer and antiviral activity of PMEG. 
_____________________________________________________________________________ 
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1. Introduction1 
 
 Since the discovery that the human immunodeficiency virus (HIV) is the causative agent of 
the acquired immunodeficiency syndrome (AIDS) [3], there have been numerous attempts to 
find remedies against this retrovirus [4,5]; in fact, against viral diseases in general [4–7]. One of 
the popular and relatively successful classes of compounds are so-called acyclic nucleoside 
phosphonates (ANPs) [8]. Among these ANPs, especially two series were and still are in the 
focus; they differ somewhat in the structure of their "alkyl" chain, that is, R-CH2-CH2-O-CH2-
PO 3
2!  versus R-CH2-CH(CH2OH)-O-CH2-PO 3
2!  [5]. 
 To the second series belongs (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine 
(HPMPC), which can be considered as an analogue of cytidine 5'-monophosphate (CMP2–) and 
of its 2'-deoxy derivative (dCMP2–) [9]. HPMPC, also known as Cidofovir, was approved in 
1996 for the treatment of cytomegalovirus retinitis in patients with AIDS [10]. However, new 
antiviral activities of HPMPC and of related analogues are still being discovered [6,7] and 
various prodrug forms are studied [11–13] which give rise to higher activities due to an increased 
bioavailability, e.g., against HIV-1 [12], herpesviruses [11] or orthopoxviruses [11]. 
                                                
1 Abbreviations: Those of the methoxyphosphonate ligands are defined in Fig. 1 and its legend.  
-- AMP2– = adenosine 5'-monophosphate; ANP2– = acyclic nucleoside phosphonate; ANPpp4– = 
diphosphorylated ANP2–; Arm = heteroaromatic nitrogen base (e.g., Bpy or Phen); ATP4– = 
adenosine 5'-triphosphate; Bpy = 2,2'-bipyridine; CMP2– = cytidine 5'-monophosphate; dCMP2– 
= 2'-deoxy-CMP2–; dGMP2– = 2'-deoxy-GMP2–; dNTP4– = 2'-deoxy-NTP4–; GMP2– = guanosine 
5'-monophosphate; I = ionic strength; Ka = acidity constant; M2+ = general divalent metal ion, 
including in part Cu(Arm)2+; NTP4– = nucleoside 5'-triphosphate; Phen = 1,10-phenanthroline; 
R-PO 3
2!  = simple phosphate monoester or phosphonate ligand with R being a non-interacting 
residue. Species denoted without a charge either do not carry one or represent the species in 
general (i.e., independent of their protonation degree); which of the two possibilities applies, is 
always clear from the context. In formulae like Cu(Arm)(H;PMEG)+, the H+ ion and PMEG2– are 
separated by a semicolon to facilitate reading, yet they appear within the same parenthesis to 
indicate that the proton is at the ligand without defining its location (see Sections 2, 3.2, and 3.3). 
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 An example of the first series mentioned above is 9-[2-(phosphonomethoxy)ethyl]adenine 
(PMEA; see Fig. 1), also known as Adefovir, which was launched in 2002 in the form of its oral 
prodrug form (Hepsera or Preveon) [14] for the treatment of patients with chronic hepatitis B 
virus infections [10]. The prodrug form improves the oral bioavailability and the passage of the 
drug through the cell membranes [15]. Once inside the cell, the acyclic nucleoside phosphonate 
(ANP) derivatives are diphosphorylated by kinases leading to their active forms, i.e., ANPpp4– 
[8,16,17]. These analogues of (2'-deoxy)nucleoside 5'-triphosphates ((d)NTP4–) [13] serve as 
excellent alternative substrates [14,18] for RNA or DNA polymerases [8,13,17], acting as 
terminators at the 3'-end of the growing nucleic acid chain [10,13] due to the lack of a 3'-OH 
group. The above also indicates the advantage of the ANPs, which only need to be 
diphosphorylated in contrast to nucleoside analogues like, e.g., the widely studied [19] Acyclovir, 
guanine(N9)-CH2-O-CH2CH2-OH, where three phosphorylation steps are needed [10]. 
 Closely related to PMEA is 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP; 
see Fig. 1), which is about as antivirally active as PMEA [20]. Interestingly, 9-[2-
(phosphonomethoxy)ethyl]guanine (PMEG; see Fig. 1) is even more active than PMEA, but it is 
also more cytotoxic, thus giving a poorer selectivity index [5,21]. However, the cytotoxic effect 
of PMEG has been evaluated for its application as antitumor agent [22]. In fact, it is active 
against human cervical cancer cells (in vitro and in vivo) [23] and non-Hodgkin's lymphoma 
[24]. Its hexadecyloxypropyl ester also inhibits ocular cell proliferation [25]. Furthermore, it 
needs to be mentioned that (N6)-substituted 2,6-diaminopurine analogues are metabolized to the 
corresponding guanine counterparts by N6-methyl-AMP aminohydrolase; thus, these compounds 
can be considered as prodrugs of PMEG [26]. Taking all this together, it is evident that the 
molecular properties of PMEG (Fig. 1) [27–31] warrant detailed studies. As a side remark one 
may mention that derivatives of guanosine and isoguanosine, due to their hydrogen-bonding and 
π-π stacking properties are used in supramolecular devices [32]. 
insert Fig. 1 close to here 
 In all instances the ANP drug is active, as mentioned above, in the diphosphorylated 
ANPpp4– form, where it constitutes a substrate as an NTP4– analogue for the polymerase. Two 
metal ions are involved in the mechanism of the polymerase reaction [33]. One of them needs to 
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be coordinated to the β,γ-phosphate unit and the other to the α-phosph(on)ate group [34–37] to 
promote the transfer of a nucleotidyl residue [14,18,38]. To achieve this M(α)-M(β,γ) 
coordination mode, the substrate needs to be correctly positioned in the active-site cavity of the 
enzyme, and here H-bonding and especially aromatic-ring stacking are expected to be important. 
In fact, π-π interactions are of relevance in recognition reactions of protein-nucleic acid adducts 
and they occur, e.g., between an indole residue of a protein-tryptophan and an adenine-RNA 
moiety in a peptide-RNA complex from a bacteriophage [39,40]. Another example is a zinc 
finger-RNA adduct with an indole residue intercalated between two guanine moieties [40,41]. 
 Since it is known [42] that substituents at one aromatic ring may directly participate in the 
stacking interactions with the other, it is of general interest to probe and to compare the stacking 
properties of the three purine ANPs shown in Fig. 1, and to see what kind of differences, if any, 
occur. Of course, the substituents at an aromatic-ring system may also contribute to the 
orientation and stability of the π-stacks, e.g., via CH/π and/or NH/π interactions [43]. As shown 
over the years, the heteroaromatic N-ligands (Arm), i.e., 2,2'-bipyridine (Bpy) and 1,10-
phenanthroline (Phen), have proven very helpful as indicators [44] for evaluating the stacking 
capabilities of aromatic residues in metal ion complexes [45] of amino acids [46,47] and 
nucleotides [45,46,48–50]. As bridging link between the two ligands containing aromatic 
moieties, most often Cu2+ was employed [1,2,45,49–51] due to its biological relevance on the 
one hand [52] and the high stability of the Cu(Arm)2+ species [53] on the other. In the present 
study we have used the same basic 'units' plus the three purine-ANPs seen in Fig. 1. 
 
2. Experimental 
 
 Twofold protonated 9-[2-(phosphonomethoxy)ethyl]guanine (H2(PMEG)±; Fig. 1) was 
synthesized according to published procedures [5,54]. All the other reagents were the same as 
used previously in recent studies [1,2], and the stock solutions were prepared as described 
[2,55,56]. This also applies to the equipment employed in the potentiometric pH titrations and 
their evaluations [57], as well as for the experimental procedures in general [55–57], including 
the determination of the concentration of the NaOH, ligand, and Cu2+ stock solutions [58]. 
 7 
 The Metrohm instruments were calibrated with buffer solutions and the direct pH meter 
readings were used in the calculations [56,57] of the acidity constants [55]. These constants of 
H2(PMEG)± regarding the Equilibria (2a), (3a), and (4a) (vide infra in Section 3.1) were 
measured as described [2] (see also [50]). Because of the direct pH meter reading these constants 
determined at I = 0.1 M (NaNO3) and 25°C are so-called practical, mixed, or Brønsted constants 
[59,60]. They may be converted into the corresponding concentration constants by subtracting 
0.02 from the listed pKa values [59]. 
 The stability constants  KM(H;PMEG)
M  (Eq. (5)) and  KM(PMEG)
M  (Eq. (6)) (see Section 3.2), where 
M2+ = Cu2+, Cu(Bpy)2+ or Cu(Phen)2+, of the binary Cu(H;PMEG)+ and Cu(PMEG) complexes, 
as well as of the ternary Cu(Arm)(H;PMEG)+ and Cu(Arm)(PMEG) complexes were determined 
as described recently [2]. The same conditions as used for the determination of the acidity 
constants were also applied now, but NaNO3 was partly replaced by Cu(NO3)2/Arm (25°C; I = 
0.1 M); for details see Ref. [2]. The individual results for the stability constants showed no 
dependence on pH or on the excess of metal ion concentrations used. The results are in each case 
the average of at least six independent pairs of titrations. 
 Finally, in studies devoted to intramolecular π-π stacks it is important to ascertain that the 
self-association of the individual reactants is negligible. With [Cu(Phen)2+] = 1.67 to 3.33 mM, 
as employed here, this goal is achieved because more than 98% of Cu(Phen)2+ are present in the 
monomeric form [2]. For Cu(Bpy)2+ this is even more true [61]. Similarly, for AMP2– and related 
adenine derivatives at concentrations of 0.3 mM about 99.9% are present in their monomeric 
form [2]. Because the self-stacking tendency of guanines is about half of that of adenines [62] 
the given 99.9% of monomer are a lower limit for PMEG2–. To conclude, the results presented in 
this study clearly refer to monomeric species. 
 
3. Results and discussion 
 
3.1. Acid-base properties of H3(PMEG)+ and of some related species 
 
The acyclic nucleotide analogue PMEG2– can accept two protons at the phosphonate group 
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and one more at the N7 site, but it can also release a proton from the (N1)H unit of the guanine 
residue (Fig. 1), giving thus rise to the following four deprotonation reactions (Eqs. (1)–(4)). 
 H3(PMEG)+  H2(PMEG)± + H+ (1a) 
  KH3(PMEG)
H  = [H2(PMEG)±][H+]/[H3(PMEG)+] (1b) 
 H2(PMEG)±  H(PMEG)– + H+ (2a) 
  KH2(PMEG)
H  = [H(PMEG)–][H+]/[H2(PMEG)±] (2b) 
 H(PMEG)–  PMEG2– + H+ (3a) 
  KH(PMEG)
H  = [PMEG2–][H+]/[H(PMEG)–] (3b) 
 PMEG2–  (PMEG – H)3– + H+ (4a) 
  KPMEG
H  = [(PMEG – H)3–][H+]/[PMEG2–] (4b) 
insert Table 1 close to here 
The corresponding pKa values of these acidity constants are listed in entry 2 of Table 1 
[57,59,63–69]. Comparison with the values of 9-ethylguanine (entry 1) and methylphosphonate 
(entry 3) or (phosphonomethoxy)ethane (entry 4) reveals that the first proton of H3(PMEG)+ is 
released from the twofold protonated phosphonate group, i.e., from P(O)(OH)2, followed by the 
proton of the (N7)H+ site and the second proton from the P(O) 2
! (OH) group. The release of the 
final proton according to Equilibrium (4a) from the (N1)H unit of PMEG2– takes place with pKa 
= 9.34 (Table 1, footnote “e”) and it is thus beyond the pKa/pH range studied in this work 
because of the hydrolysis of Cu aq
2+ . However, it is interesting to note here that the binary stacks 
of (Phen)(Guo) and (Phen)(Guo – H)– have, within the error limits, the same stability (K = 42 ± 6 
M–1 (2σ) [44]) despite the negatively charged (N1)– in the second adduct. 
Entries 4 and 5 of Table 1 referring to (phosphonomethoxy)ethane and 9-methyladenine 
allow an unequivocal site attribution for the deprotonation reactions of H3(PMEA)+ and 
H3(PMEDAP)+ (see Fig. 1); the first proton being released from P(O)(OH)2 followed by the one 
from (N7)H+. The third and final proton is released from the P(O) 2
! (OH) group. Both acyclic 
nucleoside phosphonates are used in the following for comparisons regarding their stacking 
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tendencies with those in adducts containing PMEG2–. 
 
3.2. Stabilities of the Cu(Arm)(H; PMEG)+ and Cu(Arm)(PMEG) complexes 
 
The experimental data of the potentiometric pH titrations of the M2+/PE systems, where M2+ 
= Cu2+, Cu(Bpy)2+ or Cu(Phen)2+ and PE2– = PMEG2– or one of the ANPs seen in Fig. 1, can be 
fully described by considering the acidity constants of H2(PE)± (Eqs. (2) and (3)) as well as 
Equilibria (5a) and (6a): 
M2+ + H(PE)–  M(H;PE)+ (5a) 
  KM(H;PE)
M  = [M(H;PE)+]/([M2+][H(PE)–]) (5b) 
M2+ + PE2–  M(PE) (6a) 
  KM(PE)
M  = [M(PE)]/([M2+][PE2–]) (6b) 
Of course, the evaluation of the experimental data ought not to be carried into the pH range 
where formation of hydroxo complexes occurs, which is evident from titrations of M2+ in the 
absence of ligand. Since the stabilities of the Cu(Bpy)2+ and Cu(Phen)2+ complexes are very high 
[53], their formation is practically complete under the experimental conditions (Ref. [2] and 
Section 2). Moreover, in formulas like M(H;PE)+ the H+ and PE2– are separated by a semicolon 
to facilitate reading, yet they appear within the same parenthesis to indicate that the proton is at 
the ligand without defining its location. 
A further important point is to note that Equilibria (5a) and (6a) are connected via 
Equilibrium (7a); the corresponding acidity constant (Eq. (7b)) can be calculated with Eq. (8): 
M(H;PE)+  M(PE) + H+ (7a) 
  KM(H;PE)
H  = [M(PE)][H+]/[M(H;PE)+] (7b) 
  pKM(H;PE)
H  =  pKH(PE)
H  + log  KM(H;PE)
M  – log  KM(PE)
M  (8) 
The constants for Equilibria (5a), (6a), and (7a) are listed in columns 3, 4, and 5 of Table 2 
for the complexes of PMEG, respectively, together with some related data for other PE ligands 
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[2,57,66,70]. The stability constants for the binary Cu(H;PMEG)+ and Cu(PMEG) complexes 
will be mainly discussed elsewhere in a different context. Herein we focus on the properties of 
the ternary complexes and use the data for the binary ones only for comparison, where needed. 
insert Table 2 close to here 
It may be added that the present evaluation and description of the various PMEG complexes 
is done in analogy to the recently described situation for several purine- and pyrimidine-
nucleotide analogues [1,2], but now, of course, the guanine residue is in the focus. 
 
3.3. Where is the proton located in Cu(Arm)(H;PMEG)+? 
 
Evidently metal ion coordination must give rise to a significant acidification due to charge 
repulsion between H+ and Cu2+. A comparison between 
 
pKH2(PMEG)
H  = 3.35 (Table 1, entry 2, 
column 4) which is due to (N7)H+ deprotonation, and  pKCu(Arm)(H;PMEG)
H  = ca. 4.9 (Table 2, entries 
2b and 2c, column 5) shows that (N7)H+ in H2(PMEG)± is more acidic than 
Cu(Arm)(H;PMEG)+, consequently the proton cannot be located at N7 but must be at the 
phosphonate group, which is expressed by writing Cu(Arm)(H·PMEG)+ or generally 
Cu(Arm)(H·PE)+. This conclusion agrees with  pKH(PMEG)
H  = 6.86 (Table 1, entry 2, column 6), 
which is due to the monoprotonated phosphonate group, and  pKCu(Arm)(H;PMEG)
H  = ca. 4.9 for the 
complexes; this corresponds to an acidification of about 2 pK units at the P(O) 2
! (OH) group.  
Of course, the above insight still leaves open the question: Where is Cu(Arm)2+ located? 
There are three possibilities: (i) Cu(Arm)2+ is together with H+ at the phosphonate residue. (ii) It 
is coordinated at N7 of the purine residue. (iii) Cu(Arm)2+ forms a stack with the guanine residue 
and this is the driving force for the formation of the Cu(Arm)(H·PMEG)+ species. Certainly, the 
actual situation could also be a combination of the three possibilities. In any case, it is evident 
that the situation is a difficult one. Therefore, we shall first have a look at the stability constants 
of the complexes assembled in Table 2, and thereafter we continue to evaluate the stabilities and 
structures of the Cu(Arm)(PMEG) complexes. Maybe these evaluations provide some hints 
about the situation in the Cu(Arm)(H·PMEG)+ species.  
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3.4. Comparison of the stability constants of the various complexes considered 
 
Three general observations follow from the data in Table 2 and warrant mentioning: 
(i) The basicity of the PO 3
2!  group of PMEG2– and PMEDAP2– is quite similar (Table 1, 
entries 2 & 7, column 6) as is the stability of their Cu(Arm)(PE) complexes (Table 2, entries 
2b/2c and 3b/3c; column 4). This contrasts with the somewhat lower stability of the 
Cu(Arm)(PMEA) complexes, even though the PO 3
2!  basicity is very similar again. This leads 
tentatively to the impression that the shape of the ANP has an influence; indeed, if stack 
formation should turn out to be important, this would make sense. 
(ii) Similarly, the basicities of the P(O) 2
! (OH) group of H(PMEG)–, H(PMEDAP)–, and 
H(PMEA)– are quite alike (Table 1; column 3), yet the stabilities of the monoprotonated 
complexes decrease in the order Cu(Arm)(H·PMEG)+ > Cu(Arm)(H·PMEDAP)+ > 
Cu(Arm)(H·PMEA)+ (Table 2). This order cannot be due to the basicity of the neutral purine 
residue, because this is lowest in the guanine one (Table 1, columns 4 and 5). Hence, this 
observation indicates indirectly again that stack formation may be of relevance.  
(iii) A comparison of the stability of the binary complexes (Table 2, entries 2a, 3a, and 4a; 
columns 3 and 4) indicates that Cu(H·PMEG)+ and Cu(PMEG) are especially stable. This might 
be due to pronounced macrochelate formation of the phosphonate-coordinated Cu2+ with the 
N7[(C6)O] site; an interaction which is sterically inhibited in complexes of PMEDAP and 
PMEA due to (C6)NH2. Indeed, it is known that a nucleobase-C(amino) group is sterically more 
demanding than a carbonyl substituent [71]; in fact, the latter is also well suited to participate in 
M2+ binding either outersphere via H-bonds or directly by innersphere coordination [72,73]. 
 
3.5. Indication for an increased stability of the mixed ligand Cu(Arm)(PMEG) complexes 
 
Already above in point (i) of Section 3.4 we have seen that the ternary Cu(Arm)(PMEG) 
complexes appear to be especially stable. Indeed, Equilibrium (9a) represents a way to describe 
the stability of ternary complexes on the basis of their parent binary complexes [74]: 
Cu(Arm)2+ + Cu(PMEG)  Cu(Arm)(PMEG) + Cu2+ (9a) 
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 10Δ log KCu = [Cu(Arm)(PMEG)][Cu2+]/([Cu(Arm)2+][Cu(PMEG)]) (9b) 
The corresponding equilibrium constant (Eq. (9b)) follows from Eq. (10): 
 Δ log KCu = log  KCu(Arm)(PMEG)
Cu(Arm)  – log  KCu(PMEG)
Cu  (10) 
According to the general rule for complex stabilities, i.e., K1 > K2, Equilibrium (9a) is expected 
to be on its left side with negative values for Δ log KCu. Indeed, statistical considerations predict 
for Δ log KCu a value of about –0.5 for the coordination of a monodentate ligand to Cu(Arm)2+ 
[75]. However, for simple phosph(on)ates Δ log KCu equals about 0.03 [70,76], in agreement 
with results obtained for mixed ligand complexes composed of a bidentate heteroaromatic amine 
and an O-donor site [74,77]. This enhanced stability was attributed to π back-bonding from the 
metal ion to the aromatic N-ligand, and this in turn favors the polar O-donor binding [77,78]. 
Comparing the above with the results listed in column 6 of Table 2 shows that Δ log KCu has 
a positive sign and is also larger than expected for all the ternary complexes, indicating that 
Equilibrium (9a) is shifted towards its right side. One may add that in the Cu(Arm)(PME) 
complexes, Δ log KCu being about 0.15 (Table 2, entry 1), the ether oxygen atom (see Fig. 1) 
participates in metal ion binding in about 75% of the species [70], that is, PME2– acts to a large 
extent as a bidentate ligand (see Section 3.7 and Ref. [1]). From this follows that in all the other 
Cu(Arm)(PE) systems, which have a nucleobase residue and a Δ log KCu value larger than about 
0.15 log units, the increased stability needs mainly to be attributed to stack formation. 
A more detailed comparison of the Δ log KCu values in Table 2 reveals that the Δ log KCu 
values of 0.30 and 0.59 for the Cu(Bpy)(PMEG) and Cu(Phen)(PMEG) systems, respectively, 
are relatively small. The reason is that the binary Cu(PMEG) is especially stable (see also point 
(iii) in Section 3.4); in fact, it is about 1.4 log units more stable than is expected for a simple 
Cu2+ coordination at PO 3
2!  (calculated with Eq. (11) in Section 3.6, vide infra). This then leads 
to a distorted and misleading view about the stability of the Cu(Arm)(PMEG) complexes. 
In other words, though the described results are helpful, the discussed PMEG example 
reveals also the great shortcoming inherent in the use of Equilibrium (9a) for the quantification 
of the present type of mixed ligand complexes. Because this quantification rests also on the 
stability of the binary complexes (Eq. (10)), which themselves may already have an increased 
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stability, thus affecting the size of Δ log KCu, the result will often not be a true reflection of the 
increased stability of the ternary complex considered. 
 
3.6. Proof of an increased stability for the Cu(Arm)(PMEG) complexes 
 
An alternative way to evaluate the stability of ternary complexes, independently of the 
properties of the binary ones, rests in the present case for Cu(Arm)(R-PO3) complexes on the 
previously established [70,79] straight-line correlations [80] for log 
 
KCu(Arm)(R-PO3)
Cu(Arm)  versus 
 
pKH(R-PO3)
H  plots (Eqs. (12) and (13)). That is, the following evaluation procedure follows closely 
previous ones [1,2,55]. In these plots R-PO 3
2!  represents phosphate monoesters or phosphonate 
ligands, in which the residue R is unable to interact with Cu(Arm)2+ [70]. The corresponding 
straight-line parameters for Cu(R-PO3) (Eq. (11)) [66,79] are given for comparison: 
log 
 
KCu(R-PO3 )
Cu  = 0.465 × 
 
pKH(R-PO3 )
H  – 0.015 (11) 
log 
 
KCu(Bpy)(R-PO3 )
Cu(Bpy)  = 0.465 × 
 
pKH(R-PO3 )
H  + 0.009 (12) 
log 
 
KCu(Phen)(R-PO3)
Cu(Phen)  = 0.465 × 
 
pKH(R-PO3 )
H  + 0.018 (13) 
The error limits of log stability constants calculated with given 
 
pKH(R-PO3 )
H  values and Eqs. 
(11), (12), and (13) are ±0.06, ±0.07, and ±0.06 (3σ), respectively, in the pH range 5–8 
[66,70,79]. Relation (11) results from equilibrium constants determined for eight different 
phosphate monoester/phosphonate ligands [66]. Equations (12) and (13) are based on constants 
measured for the ternary Cu(Arm)(R-PO3) complexes, where R-PO 3
2!  = D-ribose 5-
monophosphate, methanephosphonate, and ethanephosphonate [70]. On these log 
 
KCu(Arm)(R-PO3 )
Cu(Arm)  
versus 
 
pKH(R-PO3 )
H  plots, also the data points measured for the corresponding methyl phosphate 
systems [76] fit, confirming the reliability of the plots. 
insert Figure 2 close to here 
The reference lines as defined by Eqs. (12) and (13) are seen in Fig. 2 [50,70,79,81], where 
the stability constants log  KCu(Arm)(PE)
Cu(Arm)  (Eq. (6)) versus the acidity constants  pKH(PE)
H  (Eq. (3)) for 
the PME2–, PMEG2–, PMEDAP2–, and PMEA2– systems of Fig. 1 are also plotted. The data 
points for dGMP2– are given for comparison. The data points for all 10 ternary complexes (see 
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also Table 2) are far above their reference lines, proving an increased stability. This must mean 
that in the Cu(Arm)(PME) systems the ether oxygen participates in metal ion binding and further 
that in the Cu(Arm)(PMEG), Cu(Arm)(PMEDAP), and Cu(Arm)(PMEA) systems the 
nucleobase moiety is responsible for the additionally observed stability enhancements, most 
likely via aromatic π-π stacking (Fig. 3) (see Section 3.7) as already indicated above. 
insert Fig. 3 close to here 
The vertical differences seen in Fig. 2 (broken lines) between the data points of the ternary 
systems and their reference lines, can be defined according to Eq. (14): 
log ΔCu/Arm/PE = log  KCu(Arm)(PE)
Cu(Arm)  – log KCu(Arm)(PE)op
Cu(Arm)  (14a) 
 = log  KCu(Arm)(PE)exp
Cu(Arm)  – log KCu(Arm)(PE)calcd
Cu(Arm)  (14b) 
Equations (12) and (13) allow calculating the stability constants for the Cu(Arm)(PE) 
species in which the metal ion is coordinated solely to the phosphonate group. This species is 
designated as the 'open' (op) isomer, i.e., Cu(Arm)(PE)op. These calculated (calcd) constants can 
now be compared with those experimentally (exp) measured (Eq. (6)) leading to Eq. (14). The 
expressions log  KCu(Arm)(PE)calcd
Cu(Arm)  (Eq. (14b)) and log  KCu(Arm)(PE)op
Cu(Arm)  (Eq. (14a)) are synonymous as 
are log  KCu(Arm)(PE)
Cu(Arm)  (Eqs. (6, 14a)) and log  KCu(Arm)(PE)exp
Cu(Arm)  (Eq. (14b)). With Eq. (14) the stability 
enhancements due to any further interactions, next to the metal ion-phosphonate coordination, 
can be unequivocally defined. It follows (see also Fig. 2) that the phosphonate group of all the 
PE2– species (Fig. 1) is the primary metal ion-binding site. The results of the indicated 
calculations are summarized in columns 3–5 of Table 3 (see below in Section 3.8). 
 
3.7. Structures and possible isomeric equilibria of the ternary Cu(Arm)(PMEG) complexes 
 
Which additional interactions or binding sites, next to that of the PO 3
2!  group, may occur or 
are possible in metal ion complexes with PE2– ligands? The most obvious case is the enhanced 
stability observed for the Cu(Arm)(PME) complexes (Fig. 2) because here in addition only an 
ether-oxygen interaction can occur. Of course, exactly the same interaction, giving rise to five-
membered chelates, may as well take place with PMEG2– containing a guanine residue (see Fig. 
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1) as well as with the other PMEs having a purine residue; hence, the following intramolecular 
Equilibrium (15) between an 'open' (op) and a chelated or 'closed' (cl) isomer, i.e., 
Cu(Arm)(PE)op and Cu)Arm)(PE)cl/O, respectively, needs to be considered: 
 
(15) 
The position of this equilibrium is defined by the dimensionless constant KI/O (Eq. (16)): 
KI/O = [Cu(Arm)(PE)cl/O]/[Cu(Arm)(PE)op] (16) 
The formation of the five-membered chelates involving the ether oxygen occurs certainly 
within the equatorial part of the coordination sphere of Cu2+ because only weak interactions are 
possible with the apical positions [82], and the stability increase as expressed for Cu(Arm)(PME) 
by log ΔCu/Arm/PME with ca. 0.6 (Eq. (14)) is substantial (Fig. 2). Quite generally, one may add 
that interactions with ether oxygen atoms or hydroxyl groups are especially favored if via a 
primary binding site five-membered chelates are formed [64,83]. 
Since the ternary Cu(Arm)(PMEG) complexes, compared with Cu(Arm)(PME), show 
further significant stability enhancements (Fig. 2), the guanine moiety (Fig. 1) must also be 
involved; most likely due to stack formation as indicated already above and as found for the 
Cu(Arm)(PMEA) [2,70] and Cu(Arm)(PMEDAP) species [2]. Indeed, stack formation between 
Arm and purine residues is well-known [44]. Hence, Equilibrium (17) is expected to occur. 
 
 
(17) 
The corresponding intramolecular and dimensionless constant KI/st is defined in Eq. (18): 
KI/st = [Cu(Arm)(PE)st]/[Cu(Arm)(PE)op] (18) 
Cu(Arm)(PE)op represents the open (op) isomer and Cu(Arm)(PE)st the stacked (st) one. 
The question at this point is: Is the observed “extra” stability enhancement (Fig. 2), next to 
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an intramolecular π-π stacking, possibly in part also due to an interaction of Cu(Arm)2+ with an 
imidazole- or pyridine-type N-atom? At a guanine residue (N1)H  is not of relevance as long as it 
is not deprotonated. Regarding the N3 site one must note that from o-aminopyridine and related 
ligands it is known that M2+ binding at the pyridine N is strongly inhibited by a neighboring NH2 
group; for Cu2+ the inhibition amounts to about 1.4 log units [84,85]. Furthermore, due to the 
bulky size of Arm in Cu(Arm)2+ a coordination at N3 is further inhibited and therefore not 
observed in complexes with a 2-aminopurine residue, like in Cu(Arm)(PME2AP), where 
PME2AP = 9-[2-(phosphonomethoxy)ethyl]-2-aminopurine [55]. Therefore, such an interaction 
is also not of relevance for Cu(Arm)(PMEG).  
Next, one has to ask: What about the imidazole-type N7? N7 is a well-known binding site 
for metal ions in complexes of nucleotides and related ligands [37,85–87]. Is this site relevant for 
the Cu(Arm)(PMEG) species? In the Cu(Arm)(PME2AP) complexes this site is best accessible 
among all the Cu(Arm)(PE) species because there is no substituent at C6. Ignoring the carbonyl 
oxygen at C6 in PMEG, because in Cu(Arm)(PMEG) there is no equatorial Cu2+ site for its 
coordination left, the situation in Cu(Arm)(PME2AP) mimics the one in Cu(Arm)(PMEG) well. 
Furthermore it is well-known that the positive and negative effects of a (C)O unit are small 
[71,72]. For Cu(Arm)(PME2AP) it was recently concluded [55] by comparing the coordination 
tendency of Cu2+ towards N7 with the inhibition due to the bulky Phen ligand that the N7 site is 
of no relevance because the indicated difference amounts to –0.17 ± 0.24 log unit. The 
corresponding evaluation for Cu(Bpy)(PME2AP) gave the difference of –0.33 ± 0.25 log unit 
[55]. This then means that there is no remarkable affinity of a phosphonate-coordinated 
Cu(Arm)2+ toward N7 of PME2AP2– left [55]. Of course, this result holds for other ternary 
systems as well, like those containing PMEG2–, PMEA2– [2] or PMEDAP2– [2]. 
From the above reasonings, it follows that next to Equilibrium (15), only Equilibrium (17) 
with the intramolecular π-π stack formation between the aromatic rings of Bpy or Phen and the 
purine residue is crucial. About this latter interaction a few more comments are needed: Space-
filling molecular models reveal [70] that a purine residue of an ANP2– like PMEA2– or PMEG2–, 
if equatorially chelated to Cu(Arm)2+ via the phosphonate group and the ether oxygen, cannot 
stack well with the aromatic rings of the also equatorially coordinated Arm; a substantial and 
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strain-free overlap of the aromatic ring systems is possible only if the ether oxygen is not 
equatorially coordinated to Cu2+. This latter situation is depicted in Fig. 3. Yet, from molecular 
models [70] it appears that an apical ether-oxygen coordination and simultaneous stack 
formation might be compatible with each other in the Cu(Arm)(PMEG) species. Hence, various 
intramolecularly stacked Cu(Arm)(PMEG) complexes are possible, including those with 
somewhat different orientations of the aromatic rings towards each other. As there is at present 
no way to distinguish these various isomers and conformers in solution from each other, we treat 
all the stacked species together and designate them as Cu(Arm)(PMEG)st or generally speaking 
as Cu(Arm)(PE)st. Note, stack formation has not only been proven in the present indirect manner 
via stability considerations but also directly by spectroscopic methods [44,45,49–51,88,89]. 
Moreover, intramolecular stack formation between a pyridyl group and a purine ring system 
occurs in the ternary, dimeric Cu2+ complex formed by 2,2'-bipyridine and monoprotonated 
adenosine 5'-monophosphate as shown for the solid state in a crystal structure study [90]. 
 
3.8. Evaluation procedure regarding the intramolecular equilibria involving three isomeric 
Cu(Arm)(PMEG) species 
 
From the reasonings in the preceding Section 3.7 it follows that Equilibria (15) and (17) are 
the relevant ones. Hence, these conclusions give rise to the Equilibrium Scheme (19): 
 
 
(19) 
The upper branch reflects Equilibrium (15) and its constant KI/O (Eq. (16)), while the lower 
branch corresponds to Equilibrium (17) and its dimensionless constant KI/st (Eq. (18)) (see also 
Fig. 3). Of course, the stability of the "open" isomer, Cu(Arm)(PE)op, is defined by Eq. (20): 
 KCu(Arm)(PE)op
Cu  = 
 
[Cu(Arm)(PE)]
[Cu(Arm)2+ ][PE]
 (20) 
Cu(Arm)2+ +  PE2– Cu(Arm)(PE)op
KI/O
KI/st
Cu(Arm)(PE)cl/O
Cu(Arm)(PE)st
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A situation as described in the Equilibrium Scheme (19) involving three isomeric 
complexes has previously been analyzed [1,2,64,89,91] and, therefore, below only those 
equations are given which are needed to understand the interrelations. 
Based on Scheme (19) the experimentally accessible equilibrium constant (6b) can be 
reformulated as in Eq. (21a) and application of Eqs. (16), (18), and (20) leads to Eq. (21b): 
 KCu(Arm)(PE)
Cu(Arm)  = 
 
[Cu(Arm)(PE)op] + [Cu(Arm)(PE)cl/O] + [Cu(Arm)(PE)st ]
[Cu(Arm)2+ ][PE2! ]
 (21a) 
 =  KCu(Arm)(PE)op
Cu(Arm) (1 + KI/O + KI/st) (21b) 
From Eq. (14) and Eq. (21) follows Eq. (22), where Cu(Arm)(PE)int/tot refers to the sum of 
all the species with an intramolecular (int) interaction: 
    KI/tot = 
 
KCu(Arm)(PE)
Cu(Arm)
KCu(Arm)(PE)op
Cu(Arm)
 – 1 (22a) 
 = 10log ΔCu/Arm/PE – 1 (22b) 
 = 
 
[Cu(Arm)(PE)int/tot ]
[Cu(Arm)(PE)op]
 (22c) 
 = 
 
[Cu(Arm)(PE)cl/O] + [Cu(Arm)(PE)st ]
[Cu(Arm)(PE)op]
 (22d) 
 = KI/O + KI/st (22e) 
Evidently, the sum of all dimensionless intramolecular equilibrium constants, KI/tot, can be 
calculated via Eq. (14) by Eq. (22b). This allows to obtain values for Cu(Arm)(PE)int/tot and thus 
also for Cu(Arm)(PE)op. Once KI/tot is known, the percentage of the total amount of species with 
an intramolecular interaction, i.e., Cu(Arm)(PE)int/tot, can be calculated according to Eq. (23): 
% Cu(Arm)(PE)int/tot = 100 × KI/tot/(1 + KI/tot) (23) 
Furthermore, in those cases where the stacked species, i.e., Cu(Arm)(PE)st, are not formed, 
the above equations reduce to the two-isomer problem seen in Equilibrium (15) and KI/tot equals 
then KI/O. The results for KI/tot and the connected data regarding the Cu(Arm)(PE) systems, where 
PE2– = PMEG2–, PMEDAP2– or PMEA2–, as well as the corresponding ones for KI/O referring to 
the Cu(Arm)(PME) complexes, are listed in Table 3. 
insert Table 3 close to here 
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The results obtained for the Cu(PME) systems (Table 3, entry 1) show that the formation 
degree of the 5-membered chelate in Equilibrium (15) is rather high with about 75%. However, 
for the three other Cu(Arm)(PE) systems which contain a nucleobase residue, it is also clear that 
KI/tot >> KI/O (cf. the values of entry 1 in column 6 with the other ones in the same column); 
therefore, it is not surprising that the total amount of species with an intramolecular interaction 
amounts to about 98% in these instances. 
 
3.9. Formation degrees of the three isomeric Cu(Arm)(PMEG) complexes and of related 
isomers 
 
A more detailed evaluation regarding Equilibrium Scheme (19) is possible based on the 
structural identity of the crucial ligand parts of PME2– and the PME derivatives containing a 
nucleobase residue (Fig. 1). If one makes the justified assumption that Cu(Arm)(PME)cl/O and 
Cu(Arm)(PE)cl/O, where PE2– = PMEG2–, PMEDAP2– or PMEA2–, have the same stability, the 
intramolecular equilibrium constant KI/O given in Table 3 (entry 1; column 6) can also be applied 
here and then, according to Equation (22e), a value for KI/st results. Now the formation degrees 
of all isomeric species of Equilibrium (19) can be calculated. The results for the three mentioned 
PE2– ligands are given in Table 4 together with related data for some NMP2– systems [50,92,93]. 
insert Table 4 close to here 
At this point many conclusions may be drawn from the data in Table 4; some are to follow: 
(i) All three isomeric complexes of Equilibrium (19) are formed in aqueous solution in 
appreciable yet rather different amounts in the six Cu(Arm)(ANP) complexes. 
(ii) The stacked Cu(Arm)(ANP)st species (Fig. 3) clearly dominate, reaching formation 
degrees between about 85 and 95%. 
(iii) Consequently, the formation degrees of the 5-membered chelates (Eq. (15)) involving 
the ether oxygen are suppressed to about 10% or less, compared with the approximately 75% 
present in the Cu(Arm)(PME) systems (Table 4; column 8). 
(iv) The KI/st values of the Bpy systems (entries 2b to 4b) are always lower by a factor of 
ca. 0.5 (within the error limits), compared to those of the Phen systems (entries 2c to 4c). This is 
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understandable because the overlap of the aromatic ring systems is expected to be more 
pronounced with the tricyclic Phen than with the bicyclic Bpy. 
(v)  Interestingly, the ANPs PMEG2– and PMEDAP2– have a very similar shape (Fig. 1) 
and indeed, the values for % Cu(Arm)(PE)st as well as the corresponding KI/st values are within 
their error limits the same (see entries 2 and 3 of Table 4). In contrast, PMEA2– (entry 4), which 
has no substituent at N2, forms the stacked Cu(Arm)(PMEA) isomers with a somewhat lower 
stability (see the KI/st values) which is in accord with the participation of substituents in stacking 
interactions [42]. 
(vi) The entries given in the lower part of Table 4 lead to the observation that stacking in 
the complexes containing an acyclic nucleotide analogue is more pronounced than in the 
complexes of the corresponding parent nucleotides; hence, the stabilities are Cu(Arm)(PMEG)st 
> Cu(Arm)(dGMP)st and Cu(Arm)(PMEA)st > Cu(Arm)(AMP)st, as is best seen from the KI/st 
values in column 7. This result is most likely due to the rigidity of the ribose ring, compared to 
the acyclic situation in PMEG2– and PMEA2– (Fig. 1) which provides more flexibility. 
(vii) Of further interest is the trend-wise observation that stacking with GMP2– (entry 6b), 
compared to AMP2– (entry 7b), is apparently more pronounced as it is also the case for PMEG2– 
(entry 2) compared to PMEA (entry 4) (see the above point (v)). As far as the differences 
between Bpy and Phen in the complexes with the NMP2– ligands are concerned, they fit into the 
picture indicated above in point (iv). 
(viii) Rather surprising is the fact that dGMP2– evidently forms more stable stacking 
adducts than GMP2– (compare KI/st for entries 5b and 6b). The reason is probably that deletion of 
the 2'-OH group at the ribose makes the nucleotide somewhat hydrophobic and less well solvated 
by water; this affects the acid-base properties of the phosphate group slightly, but even more so 
those of the guanine residue [94], which is in accord with the increased stacking tendency. 
To conclude, especially the observations summarized in points (ii), (v), (vi), and (viii) are 
relevant for the anchoring process of the substrate in the active-site cavity of the nucleic acid 
polymerase; a correctly adjusted and orientated substrate is crucial for the reaction (see second to 
the last paragraph in Section 1). 
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3.10. Isomeric equilibria involving the ternary and monoprotonated Cu(Arm)(H·PMEG)+ 
species 
In Section 3.3 we have seen that the proton in the monoprotonated ternary complexes (Table 
2, column 3) is located at the phosphonate group. In Section 3.7 it was concluded that the 
aromatic N sites, i.e., N1 [2], N3, and N7 are not relevant for Cu2+ coordination but that stack 
formation is important. However, still the questions remain: Where is Cu(Arm)2+ coordinated 
and in which interactions is it involved? Does the monoprotonated  P(O)2
! (OH)  residue 
participate in Cu(Arm)2+ binding? 
In the context of the latter question it was recently concluded [83] that a  P(O)2
! (OH)  residue 
may act as a primary binding site allowing coordination of further sites. The stability constant for 
this complex formation was estimated based on previous considerations [95] as log 
 
KCu(Arm)[P(O)2 (OH)]
Cu(Arm)  = 1.0 ± 0.2 and this value was set equal to log  KCu(Arm)(H!PE)op
Cu(Arm)  [1,2]. Very 
recent experiments regarding the metal ion-binding properties of an  R(O)2
! (OH)  residue have led 
to new insights and further estimates [96], giving on average log 
 
KCu[ROP(O)2OR']
Cu   = 1.35. Since on 
the one hand heteroaromatic amines like Bpy or Phen may favor the interaction with an O-donor 
site [74–78] (Section 3.5), yet on the other, the interaction with a monoprotonated phosph(on)ate 
group may occur [96], at least in part, in an outersphere manner [87,97] with a water molecule 
between  P(O)2
! (OH)  and M2+, we estimate (with a generous error limit) log 
 
KCu[ROP(O)2OR']
Cu  = 1.3 
± 0.2 and set this value equal to  log  KCu(Arm)(H!PE)op
Cu(Arm) . With the monoprotonated phosphate group 
now defined as primary binding site, a scheme analogous to the Equilibrium Scheme (19) can be 
proposed, i.e., in Scheme (19) PE2– simply needs to be replaced throughout by H·PE–; the same 
holds for the connected Eqs. (14) to (23). Hence, we are now in the position [1,2] to evaluate the 
available data for the Cu(Arm)(H·PMEG)+ and its related species, though, as we will see below, 
there is a caveat with regard to the structure of the stacks. 
After having defined the stability of the Cu(Arm)(H·PMEG) op
+   complexes, one may 
calculate, by using the measured stability constants of column 3 in Table 2, the stability 
enhancements, log ΔCu/Arm/H·PMEG, as defined in analogy to Eq. (14). The results together with 
 KI/tot
*  and % Cu(Arm)(H·PMEG) int/tot
+  (calculated in analogy to Eqs. (22b) and (23)) are 
compiled in Table 5. For comparison the revised results (cf. with [1,2]) obtained for 
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Cu(Arm)(H·PMEA)+ and Cu(Arm)(H·PMEDAP) are also listed. 
insert Table 5 close to here 
The results of Table 5 can be further analyzed by using the KI/O values obtained for the 
Cu(Arm)(PME) complexes (see Section 3.7 plus Tables 3 and 4), because the corresponding 
stability enhancements due to the interaction with the ether O-atom (Equilibrium (15)) are 
expected [83] to be independent from the metal ion affinity of the primary binding site. The 
remaining calculations were carried out analogously to those for the Cu(Arm)(PE) systems given 
in Table 4. The formation degrees of the various isomers (analogous to Scheme (19)) of the 
monoprotonated ternary Cu(Arm)(H·PMEG)+ complexes (but see the caveat below) are collected 
in Table 6, together with those for the Cu(Arm)(H·PMEDAP)+ and Cu(Arm)(H·PMEA)+ ones. 
insert Table 6 close to here 
Among the conclusions to be drawn from the data in Table 6 are certainly the following 
ones: 
(i) All three isomeric complexes, i.e., Cu(Arm)(H·PE) op
+ , Cu(Arm)(H·PE) cl/O
+ , and 
Cu(Arm)(H·PE) st
+ , occur in appreciable amounts (Table 6; columns 5, 8, 9), as it is also the case 
for the uncharged Cu(Arm)(PE) species (Table 4). 
(ii) As expected, in all instances it holds: % Cu(Bpy)(H·PE) st
+  < % Cu(Phen)(H·PE) st
+  (see 
also the  KI/st
*  values in column 7). 
(iii) For the Cu(Arm)(H·PMEG)+ and the Cu(Arm)(H·PMEDAP)+ systems (entries 2 and 
3) the stacked isomers clearly dominate, whereas for the Cu(Arm)(H·PMEA) complexes it 
appears that the Cu(Arm)(H·PMEA) cl/O
+  and Cu(Arm)(H·PMEA) st
+  isomers form in more 
comparable amounts (see in this context footnotes "e" and "f" of Table 6). 
(iv) For the Cu(Arm)(PMEG) (Table 4) and Cu(Arm)(H·PMEG)+ (Table 6) systems it 
appears that the formation degrees of the stacked species are practically identical. However, this 
conclusion may be compromised by the caveat given below in Section 3.11, whereas for the 
PMEDAP complexes one may be relatively confident that it holds % Cu(Arm)(PMEDAP)st > % 
Cu(Arm)(H·PMEDAP) st
+  (entries 3 in Tables 4 and 6). 
(v) Superficially, the high formation degrees of about 92 to 94% for the 
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Cu(Arm)(H·PMEG) st
+  isomers appear as most impressive in Table 6. These formation degrees 
are significantly larger (entry 2) than any other in Table 6 and this is striking, especially if 
compared with the situation summarized in Table 4 for the neutral Cu(Arm)(PE) systems. 
 
3.11. A caveat regarding the evaluation of the monoprotonated Cu(Arm)(H·PMEG)+ systems 
 
A more careful look at the data regarding the Cu(Arm)(H·PMEG)+ systems assembled in 
Table 5 reveals the caveat regarding the conclusion given above in point (v) of Section 3.10: The 
monoprotonated phosphonate residue of H(PMEG)– is no longer the dominating "primary" 
binding site because log  KCu(Arm)(H!PMEG)op
Cu(Arm)  = 1.3 ± 0.2 is smaller than the stability enhancements 
log ΔCu/Arm/H·PMEG which amount to about 1.8 log units (Table 5, entry 2, column 4) indicating the 
importance of another site. Hence, the data given for Cu(Arm)(H·PMEG)+ in Table 6 (entry 2) 
need to be considered with some reservation (see further below). 
As far as the Cu(Arm)(H·PMEDAP)+ systems are concerned, the two values, that is, log 
 KCu(Arm)(H!PMEDAP)op
Cu(Arm)  = 1.3 ± 0.2 and log ΔCu/Arm/H·PMEDAP = 1.08 ± 0.22 or 1.26 ± 0.22 (Table 5, 
entry 3, column 4), are close to each other, but the results given in Tables 5 and 6 are still valid 
in a first approximation. This conclusion is supported by the observation that the percentages 
calculated previously [2] for Cu(Arm)(H·PMEDAP) st
+ , which were based on log 
 KCu(Arm)(H!PMEDAP)op
Cu(Arm)  = 1.0 ± 0.2, are within the error limits the same (see Table 6 in [2]) as those 
calculated now (Table 6, entry 3). 
However, what does the observation regarding Cu(Arm)(H·PMEG)+ as indicated above and 
also in point (v) of Section 3.10 actually mean? It means that the unbridged aromatic-ring stack, 
which actually may be considered as a 'binary' stack, symbolized as Cu(Arm)2+/(H·PMEG)–, 
contributes to the stability enhancement log ΔCu/Arm/H·PMEG = ca. 1.8! Therefore, the percentages 
listed in Table 6 (entry 2, column 9) refer to the sum of the unbridged plus the Cu2+-bridged 
stacks (analogous to Fig. 3). 
The consequence of the above is that there are two 'open' species, namely 
Cu(Arm)(H·PMEG) op
+ , where Cu2+ is at the phosphonate group, and Cu(Arm)2+/(H·PMEG) op
! , 
that is, the unbridged stack. Each of these two open complexes can lead to the Cu2+-bridged 
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stack, Cu(Arm)(H·PMEG) st
+ ; once via the Cu2+-phosphonate coordinated species, and once via 
the unbridged (binary-like) stack. In addition, Cu(Arm)(H·PMEG) op
+  may of course still form 
the five-membered chelate, Cu(Arm)(H·PMEG) cl/O
+ , in analogy to Eq. (15). These reasonings 
lead to the Equilibrium Scheme (24), where M2+ = Cu(Arm)2+ and (H·PE)– = (H·PMEG)–: 
 
 
 
 
 
             (24) 
The definitions of the two stability constants of the open complexes,  KM(H!PE)op
M  = 
 KCu(Arm)(H!PMEG)op
Cu(Arm)  (analogous to Eq. (20)) and  KM/(H!PE)op
M  =  KCu(Arm)/(H!PMEG)op
Cu(Arm) , follow from the 
Equilibrium Scheme (24); their dimension is M–1. Similarly, the definitions of all four 
dimensionless intramolecular equilibrium constants, KI, also follow from Scheme (24). 
One could try to make guesses for the stabilities of the two open complexes and this would 
then also provide a value for KI/op because Eq. (25) holds: 
KI/op = 
 
[M2+ /(H !PE)op" ]
[M(H !PE)op+ ]
 =  KM/(H!PE)op
M / KM(H!PE)op
M  (25) 
Furthermore, KI/O could be assumed as being known as was done before (Section 10, Table 6). 
However, regarding KI(St,op)St and/or KI(P,op)St we were not able to come up with a convincing 
estimate based on information available to us. Hence, we decided to leave it to the interested 
readers to make their own guesses regarding the formation degree of the stacked M(H·PE) st
+  (= 
Cu(Arm)(H·PMEG) st
+ ) species under the indicated conditions. However, that both stacks, 
Cu(Arm)(H·PMEG) st
+  and Cu(Arm)2+/(H·PMEG) op
! , form is certain from the results in Table 6 
and the above discussion. 
 
4. Concluding remarks 
 
KM/(H·PE)op
M2+ + (H·PE)–
KI/op
M(H·PE)+
M2+/(H·PE)–
KI(P,op)St
KI(St,op)St
KI/O
M(H·PE)+
M(H·PE)cl/O
op
st
M
KM(H·PE)opM
op
+
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The ANPs seen in Fig. 1 show antiviral activity, PMEA being already in use as a therapeutic 
agent. The antiviral activities of PMEDAP are similar and those of PMEG are even more 
pronounced. Most remarkably, PMEG also shows anticancer activities (see Section 1). If one 
compares the extent of stacking in the Cu(Arm)(ANP) systems, one notes that PMEA2– forms the 
least stable stacks, whereas those of PMEG2– and PMEDAP2– are of a higher and comparable 
stability (Table 4, columns 7 and 9); this equality is attributed to shape complementarity (Section 
3.9, point (v)), though overall PMEG2– seems actually to be slightly favored in stack formation. 
Indeed, the excellent stacking properties of PMEG2– are especially borne out in the 
monoprotonated Cu(Arm)(H·PMEG)+ complexes; here the stability enhancement log 
ΔCu/Arm/HPMEG (analogous to Eq. (14)) is even larger than the metal ion affinity of the "primary" 
binding site, i.e., of the P(O) 2
! (OH) group (cf. Table 5). This means that the "open" (op) and 
unbridged Cu(Arm)2+/(H·PMEG) op
!  stack, which actually may be considered as a "binary" stack, 
contributes significantly to the observed stability enhancement (Section 3.11). Possibly the 
remarkable cytotoxic properties of PMEG are a reflection of its intense stacking qualities, which 
outrun in complexes those of its parent nucleotides dGMP and GMP (Table 4, columns 7 and 9). 
Another well-known aspect is that the ether oxygen of the PME chain (Fig. 1) is compulsory 
for the antiviral activity of the ANPs [98,99]. In accord herewith, 9-(4-phosphonobutyl)adenine 
(= 3'-deoxy-PMEA2–) is devoid of any antiviral activity [98]. It is most likely that the ether 
oxygen facilitates achieving the two metal ion-containing [33] M(α)-M(β,γ) coordination mode 
needed for the transfer of a nucleotidyl residue [14,18,38] in the nucleic acid polymerase 
reaction. This ether-oxygen effect can be modulated via stacking (Section 3.9; point (iii)) and 
PMEG2– appears here to be especially effective: It reduces in Cu(Arm)(PMEG) the ether-oxygen 
interacting species to about 5% compared to the ca. 75% occurring in the Cu(Arm)(PME) 
systems. Though the details are not yet well understood, it is clear that upon mixed ligand 
complex formation the metal ion-ether oxygen interaction is affected and thus modulated. 
Another interesting observation with regard to mechanistic considerations is the larger 
formation degree of the stacked isomers in the acyclic Cu(Arm)(PMEG) species compared with 
the parent complex, Cu(Arm)(dGMP) (Table 4). In fact, based on the results assembled in Table 
4, several points of relevance for the anchoring process of the substrate in the active-site cavity 
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of a nucleic acid polymerase, were already discussed in points (ii), (v), (vi), and (viii) of Section 
3.9, and shall not be repeated here. 
A final point to be emphasized is that the changes in free energy (ΔG0) connected with 
intramolecular equilibria like metal ion-ether oxygen or stacking interactions are small, which 
means that an equilibrium can easily be shifted from one side to another. For example, a stability 
enhancement of log Δ = 0.1 (Eq. (14)) corresponds at 25°C only to a change in ΔG0 of 0.57 kJ 
mol–1, yet the formation degree of the closed/stacked species increases from zero to ca. 20% (see 
[2] and for details [79]). 
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Table 1 
Negative logarithms of the acidity constants of H3(PMEG)+ [Eqs. (1) to (4)] together with 
those of some related species as determined by potentiometric pH titrations in aqueous 
solution at 25°C and I = 0.1 M (NaNO3)a,b. 
No. 
Protonated 
Species 
pKa for the site 
  Ref. 
  P(O)(OH)2      (N7)H+    (N1)H+ P(O) 2
! (OH) 
1 H(9EtG)+  3.27 ± 0.03     [63]c 
2 H3(PMEG)+ 1.18 ± 0.05d 3.35 ± 0.03  6.86 ± 0.01     –e 
3 CH3P(O)(OH)2 2.10 ± 0.03   7.51 ± 0.01 [65] 
4 H2(PME) 1.57 ± 0.15f   7.02 ± 0.01 [66] 
5 H(9MeA)+  (2.96 ± 0.10)g 4.10 ± 0.01  [68] 
6 H3(PMEA)+ 1.22 ± 0.05d  4.16 ± 0.02 6.90 ± 0.01 [66] 
7 H3(PMEDAP)+ 1.26 ± 0.05d  4.82 ± 0.01 6.94 ± 0.01 [57] 
a  So-called practical, mixed or Brønsted constants are given (see Section 2 and Ref. [59]). 
b  The error limits given are three times the standard error of the mean value (3σ) or the sum 
of the probable systematic errors, whichever is larger. The error limits of derived data (e.g., 
entries No. 2, 6, and 7 in column 3) were calculated according to the error propagation after 
Gauss. 
c  Deprotonation of (N1)H in 9EtG occurs with  pK9EtG
H  = 9.57 ± 0.05 [63]. 
d  Estimate based on 
 
pKP(O)(OH)2
H  = 
 
pKP(O)2 (OH)
H  – (5.68 ± 0.05); for details see Ref. [64]. 
e  This work. Deprotonation of the (N1)H site in PMEG2– occurs with  pKPMEG
H  = 9.34 ± 0.02 
(Eq. (4)). 
f  Estimate; see Ref. [67]. 
g  This micro acidity constant reflects the basicity of N7 under conditions where N1 does not 
carry a proton; i.e.,  pkH!N7-N1
N7-N1  = 2.96 ± 0.10 holds for the species +H·N7(9MeA)N1. For the 
macro acidity constant 
 
pKH2(9MeA)
H  = –0.64 ± 0.06 holds as measured by UV 
spectrophotometry [68,69]. 
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Table 2 
Logarithms of the stability constants of the ternary Cu(Arm)(H;PMEG)+ [Eq. (5)] and 
Cu(Arm)(PMEG) [Eq. (6)] complexes, as well as of some related species, as determined by 
potentiometric pH titrations in aqueous solution, together with the negative logarithms of the 
acidity constants [Eqs. (7), (8)] of the Cu(Arm)(H;PE)+ complexes (25°C; I = 0.1 M, NaNO3)a. 
The values of the binary complexes (entries (1a), (2a), (3a), and (4a)) as well as the resulting 
stability differences [Eq. (10)] are given for comparison. 
No. M(PE) log  KM(H;PE)
M  log  KM(PE)
M   pKM(H;PE)
H  Δ log KCu Ref. 
1a Cu(PME) – 3.73 ± 0.03 – – [66] 
1b Cu(Bpy)(PME) – 3.86 ± 0.03 – 0.13 ± 0.04 [70] 
1c Cu(Phen)(PME) – 3.90 ± 0.04 – 0.17 ± 0.05 [70] 
2a Cu(PMEG) 3.26 ± 0.09 4.57 ± 0.08 5.55 ± 0.12 – –b 
2b Cu(Bpy)(PMEG) 3.01 ± 0.08 4.87 ± 0.10 5.00 ± 0.13 0.30 ± 0.13 –b 
2c Cu(Phen)(PMEG) 3.15 ± 0.10 5.16 ± 0.13 4.85 ± 0.16 0.59 ± 0.15 –b 
3a Cu(PMEDAP) 1.88 ± 0.07 3.94 ± 0.04 4.88 ± 0.08 – [57] 
3b Cu(Bpy)(PMEDAP) 2.38 ± 0.08 4.90 ± 0.03 4.42 ± 0.09 0.96 ± 0.05 [2] 
3c Cu(Phen)(PMEDAP) 2.56 ± 0.08 5.09 ± 0.04 4.41 ± 0.09 1.15 ± 0.06 [2] 
4a Cu(PMEA) 1.48 ± 0.16 3.96 ± 0.04 4.42 ± 0.17 – [66] 
4b Cu(Bpy)(PMEA) 1.77 ± 0.11 4.70 ± 0.02 3.97 ± 0.11 0.74 ± 0.04 [70] 
4c Cu(Phen(PMEA) 2.20 ± 0.09 4.97 ± 0.03 4.13 ± 0.10 1.01 ± 0.05 [70] 
a  For the error limits see footnote "b" of Table 1, and for the structure of the ligands see Fig. 1. 
b  This study. 
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Legends for the Figures 
 
Fig. 1.   Chemical structures of the dianions of 9-[2-(phosphonomethoxy)ethyl]guanine  
(PMEG2–), 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA2–), and 9-[2-
(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP2–) together with the structure of 
(phosphonomethoxy)ethane [= PME2– = (ethoxymethyl)phosphonate for R = H]. The four 
compounds are abbreviated as PE2–. The orientation of PMEA2– (and the same may be assumed 
for PMEG2–) in solution [27] and in the solid state [28] resembles the anti conformation of 
adenosine 5'-monophosphate (AMP2–) [29,30]. The structure of 2'-deoxyguanosine 5'-
monophosphate (dGMP2–) shown in its dominating anti conformation [30,31] at the bottom of 
the figure, is given for comparison (see text). 
 
Fig. 2.   Evidence for an enhanced stability of ternary Cu(Arm)(PE) complexes, where Arm = 
Bpy (empty symbols) or Phen (full symbols), and PE2– = PME2– (¯,¿), PMEG2–(£,¢), 
PMEDAP2– (r,p), or PMEA2– (,), based on the relationship between log 
 
KCu(Arm)(R-PO3)
Cu(Arm)  or 
log  KCu(Arm)(PE)
Cu(Arm) , and 
 
pKH(R-PO3)
H  or  pKH(PE)
H  in aqueous solution at I = 0.1 M (NaNO3) and 25ºC. 
The plotted data are from Tables 1 and 2. The two reference lines represent the log 
 
KCu(Arm)(R-PO3)
Cu(Arm)  versus 
 
pKH(R-PO3)
H  relationship for the ternary Cu(Arm)(R-PO3) complexes (Eqs. 
(12) and (13)); R-PO 3
2–  symbolizes phosphonates or phosphate monoesters in which the group 
R is unable to undergo any kind of hydrophobic, stacking, or other type of interaction, i.e., 
ligands like D-ribose 5-monophosphate, methanephosphonate or ethanephosphonate [70,79,81]. 
The broken line holds for Arm = Bpy and the solid line for Arm = Phen. Both straight lines 
represent the situation for ternary complexes without an intramolecular ligand–ligand 
interaction. The vertical dotted lines emphasize the stability differences from the reference lines; 
they equal log ΔCu/Arm/PE as defined in Eq. (14). The data points for Cu(Arm)(dGMP) (✩,★) are 
given for comparison; the corresponding constants are listed in Ref. [50]. 
 
Fig. 3.   Tentative and simplified structure of a Cu(Phen)(PMEG) species with an intramolecular 
stack. The orientation of the aromatic rings may vary among the stacked species; such a stacked 
complex in solution should not be considered as being rigid. 
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Synopsis 
 
The guanine residue of 9-[2-(phosphonomethoxy)ethyl]guanine leads to intense intramolecular 
stacks in the ternary complex formed with Cu(1,10-phenanthroline)2+ (aqueous solution). 
Stacking is more pronounced than with the adenine derivative. The formation degrees of the 
three isomers, PO 3
2! -coordination only, five-membered chelate with the ether-O, and the 
intramolecular guanine/phenanthroline stack, are determined. 
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